Non-Hodgkin lymphoma (ICD10 C82-C85 & C96): combined sexes
Five-year relative survival by diagnosis year and age at diagnosis
|
Five-year relative survival (with 95% confidence interval) by diagnosis year |
EUROCARE-4 |
EUROCARE-4 |
||||||||||
|
Age at diagnosis |
1994-97 |
1998-2002 |
2003-2007 |
2007-2009 |
##2000-2002 |
##2000-2002 |
||||||
|
cohort |
cohort |
cohort |
*hybrid |
Ireland |
Europe average |
|||||||
|
all 15-99 |
52.9% |
57.2% |
67.7% |
68.2% |
||||||||
|
(unstandardized) |
(49.8-55.8%) |
(54.7-59.5%) |
(64.9-70.3%) |
(65.3-70.9%) |
||||||||
|
all 15-99 |
47.6% |
51.2% |
61.1% |
61.6% |
52.0% |
54.6% |
||||||
|
(age-standardized)# |
(41.2-53.9%) |
(46.0-56.2%) |
(55.3-66.7%) |
(55.5-67.3%) |
(47.5-56.9%) |
(52.7-56.6%) |
||||||
|
15-44 |
67.4% |
72.1% |
83.6% |
84.5% |
||||||||
|
(60.8-73.1%) |
(66.8-76.6%) |
(78.9-87.4%) |
(78.9-88.8%) |
|||||||||
|
45-54 |
63.1% |
68.7% |
76.6% |
78.6% |
||||||||
|
(56.4-69.1%) |
(63.3-73.4%) |
(70.8-81.5%) |
(72.2-83.8%) |
|||||||||
|
55-64 |
55.8% |
62.0% |
72.8% |
74.7% |
||||||||
|
(49.7-61.5%) |
(57.1-66.5%) |
(68.1-76.9%) |
(69.3-79.4%) |
|||||||||
|
65-74 |
43.9% |
49.3% |
62.7% |
63.9% |
||||||||
|
(38.2-49.5%) |
(44.4-54.0%) |
(56.6-68.4%) |
(57.8-69.4%) |
|||||||||
|
75-99 |
33.5% |
32.2% |
38.6% |
36.4% |
||||||||
|
(26.3-41.3%) |
(26.7-38.1%) |
(31.8-45.6%) |
(29.5-43.7%) |
|||||||||
|
Footnotes: |
|
|
*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period, |
|
|
supplemented by follow-up 2005-2009 for cases diagnosed in 2005 or 2006 (to provide more reliable estimation of the first two years of survival). |
|
|
In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data. |
|
|
# Age-standardized figures use the standard patient population proposed for this cancer by: |
|
|
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316. |
|
|
(Population weights = age 15-44 x7000, 45-54 x12000, 55-64 x23000, 65-74 x29000, 75-99 x29000) |
|
|
## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 study: |
|
|
Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796. |
|
|
Exclusions (as in EUROCARE): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient |
|
|
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour. |
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|